Oncocyte Corp
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
IMDX$2.47-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net revenue | $115 | $429 | $395 | $1,189 |
| Cost of revenues | 43 | 159 | 184 | 593 |
| Cost of revenues – amortization of acquired intangibles | 22 | 22 | 66 | 66 |
| Gross profit | 50 | 248 | 145 | 530 |
| Operating expenses: | ||||
| Research and development | 2,817 | 2,185 | 7,582 | 6,747 |
| Sales and marketing | 1,043 | 713 | 2,742 | 2,213 |
| General and administrative | 2,565 | 2,487 | 7,645 | 9,430 |
| Change in fair value of contingent consideration | 7,140 | (435) | 9,421 | (16,947) |
| Impairment losses | — | 1,811 | — | 6,761 |
| Impairment loss on held for sale assets | — | — | 169 | 1,283 |
| Total operating expenses | 13,565 | 6,761 | 27,559 | 9,487 |
| Loss from operations | (13,515) | (6,513) | (27,414) | (8,957) |
| Other (expenses) income: | ||||
| Interest expense | (31) | (14) | (54) | (39) |
| Unrealized (loss) gain on marketable equity securities | — | (89) | — | 8 |
| Other income, net | 53 | 127 | 316 | 125 |
| Total other income, net | 22 | 24 | 262 | 94 |
| Loss from continuing operations | (13,493) | (6,489) | (27,152) | (8,863) |
| Loss from discontinued operations (Note 11) | — | — | — | (2,926) |
| Net loss | $(13,493) | $(6,489) | $(27,152) | $(11,789) |
| Net loss per share (Note 2): | ||||
| Net loss from continuing operations - basic and diluted | $(13,493) | $(6,687) | $(27,415) | $(9,602) |
| Net loss from discontinued operations - basic and diluted | $— | $— | $— | $(2,926) |
| Net loss attributable to common stockholders - basic and diluted | $(13,493) | $(6,687) | $(27,415) | $(12,528) |
| Net loss from continuing operations per share - basic and diluted | $(0.98) | $(0.81) | $(2.36) | $(1.29) |
| Net loss from discontinued operations per share - basic and diluted | $— | $— | $— | $(0.39) |
| Net loss attributable to common stockholders per share - basic and diluted | $(0.98) | $(0.81) | $(2.36) | $(1.68) |
| Weighted average shares outstanding - basic and diluted | 13,714 | 8,256 | 11,624 | 7,446 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.